aboutusmain logo














Dr. Irach B. Taraporewala

Chief Executive Officer

Dr. Irach B. Taraporewala is a seasoned pharmaceutical executive with over 25 years experience in drug development and regulatory strategy. He is a hands-on CEO with strong scientific background combined with significant management, leadership, business development, and financing experience.

Dr. Taraporewala is the founder and Managing Member of Sitara Pharmaceutical Consulting, LLC, providing consulting services to biotechnology companies on business strategy, regulatory strategic planning for small molecule and biological pharmaceuticals, nanotechnology drugs and drug-device combination products.


Dr. Taraporewala was previously the founding CEO and President of Ohr Pharmaceutical, Inc. ("Ohr"), from April 2010 until December 2015. During his 5 years of leadership at Ohr, he played a critical role in taking the company from preclinical stage through successful Phase II clinical trials.  His achievements included technology assessment and opportunity identification, followed by due diligence for potential acquisitions. He led the acquisition of the lead compound Squalamine by Ohr, He was personally involved in successfully formulating the drug as an eye drop, completing FDA IND-enabling preclinical studies, and advancing the drug product through multiple Phase 2 clinical trials in retinal diseases. Results of human clinical trials in macular degeneration, diabetic retinopathy and retinal vein occlusions showed positive visual acuity benefits in patients.


Additionally, while at Ohr, he managed external contracts and manufacturing relationships, with particular attention to regulatory CMC and QA/QC aspects. Further, he managed the successful acquisition by Ohr of an ophthalmic research company, SKS Ocular, LLC. In addition, he established a joint venture spin-off between Ohr and Cold Spring Harbor Laboratory, called DepYmed, for further clinical development of certain oncology assets. Throughout his tenure as CEO of Ohr, Dr. Taraporewala ensured that the Company was well capitalized, oversaw the up-listing of the Company's common stock to the NASDAQ exchange, and completed several successful rounds of financing.

Prior to Ohr, Dr. Taraporewala was Vice President of Regulatory Affairs and Clinical Research at Mystic Pharmaceuticals Inc., Austin, TX, from April 2008 to March 2010. At Mystic, he led the regulatory strategy for the Company's ophthalmic and intranasal drug products, as well as drug delivery systems. He played a key role in advancing the Company's technology from lab bench research into clinical trials stage.  Earlier, Dr. Taraporewala served at a well-known pharmaceutical consulting and clinical research organization, PAREXEL International Corp., as Senior Consultant in the Drug Development Consulting Division. In this position, he provided technical expertise and regulatory advice to small and large biotechnology and pharmaceutical company clients worldwide.


Dr. Taraporewala also has a track record of being awarded multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) in the areas of development of antiviral drugs, DNA-based cancer diagnostics, and from the United States Department of Defense (DoD) for antimalarial drug development, all as the Principal Investigator.

Dr. Taraporewala holds a Ph.D. degree in Medicinal Chemistry from the Philadelphia College of Pharmacy, University of the Sciences in Philadelphia (1984).  He holds a Master of Science degree in Organic Chemistry, and a Bachelor of Science degree in Chemistry and Microbiology, both from the University of Bombay, India.

CMC : "Chemistry, Manufacture, and Control" of a drug product as per US FDA guidelines and similar ICH guidances.
QA/QC : Quality Assurance and Quality Control of Drug Product.
CRO : Contract/Consulting/Clinical Research Organizations]





















Anil R. Diwan, PhD

Chairman, President

Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company's 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company's financing efforts since 2010.

Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan's leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
























Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

interim Chief Financial Officer

Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for "Mr. Coffee" and "Health-O-Meter" brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature - India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances' Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

Ms. Vyas holds a MBA in Finance from Columbia University's Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
























Eugene Seymour MD, MPH

CEO Emeritus

Dr. Seymour co-founded NanoViricides, Inc. in 2005 to commercialize ground-breaking novel nanomedicine technologies against viruses that he characterized as "'penicillin' against viruses."

Dr. Seymour has been a driving force in building NanoViricides from a nanomedicines concept to a Company with a broad pipeline of pre-clinical drug candidates against a large number of virus targets.

He resigned as CEO and as a Director of the Company at the end of January, 2018, at an age of 77, to allow a successor with pharmaceutical background in shepherding drugs through the process of FDA approval. His Severance Agreement was finalized at the end of May, 2018.

Dr. Seymour began practicing medicine in Los Angeles/ Beverly Hills in the late 1960's. In late 1981, he began treating patients with a strange new disease affecting primarily the gay population. In 1986, he was requested by the US government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. His laboratory ended up testing over 50,000 people. Because of his belief that prevention, in the absence of a cure, was critical to stem the rising tide of HIV infections, he founded a company, now called Stat-Sure, Inc, in 1989. He raised the capital and oversaw the development of a rapid HIV antibody blood test (Hema-Strip). In 1993, as Chief Executive Officer, he took the company public as a NASDAQ company. Under his direction, the company conducted research studies in Africa, Asia, South and North America. The Hema-Strip was approved in a number of countries including Canada, Great Britain and Vietnam. Dr. Seymour left the company in 1996 to run a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. He became a consultant to the UN Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia and Russia) to interact with local physicians and assist them in setting up testing programs. Two years later, he became Director of Strategic Alliances at a medical education startup called medschool.com that was later acquired by a group of investors.

Dr. Seymour is the holder of 8 issued patents. Originally trained as a chemist, he decided to attend medical school in preparation for a career as a clinical investigator. Following postgraduate medical training, he obtained a Master's degree in the Epidemiology of Infectious Diseases at UCLA. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He left UCLA after two years and joined USC faculty as Associate Professor. He served in the Medical Corps of US Army Reserve during the Vietnam era and attained the rank of Major.


























Contact Information

NanoViricides, Inc.
1 Controls Drive,
Shelton, CT 06484

Phone: +1-203-937-6137
Phone: +1-888-591-3579
Fax: +1-203-859-5095
E-mail: info@nanoviricides.com